Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-05-26 4:17 pm Unchanged | 13D | GAMIDA CELL LTD GMDA | NOVARTIS PHARMA AG | 4,336,759 4.1% | 0 (Unchanged) | View |
| 2023-03-03 4:02 pm Sale | 13D | GAMIDA CELL LTD GMDA | NOVARTIS PHARMA AG | 4,336,759 5.8% | -857,295 (-16.51%) | View |
| 2022-12-19 4:21 pm Purchase | 13G | ERASCA INC ERAS | NOVARTIS PHARMA AG | 12,307,692 8.2% | 12,307,692 (New Position) | View |
| 2022-06-27 4:37 pm Purchase | 13G | PRECISION BIOSCIENCES INC DTIL | NOVARTIS PHARMA AG | 12,407,440 16.6% | 12,407,440 (New Position) | View |
| 2021-10-08 4:07 pm Purchase | 13G | SOMALOGIC INC SLGC | NOVARTIS PHARMA AG | 10,367,340 5.7% | 10,367,340 (New Position) | View |
| 2021-03-11 4:35 pm Unchanged | 13D | GAMIDA CELL LTD GMDA | NOVARTIS PHARMA AG | 5,194,054 8.8% | 0 (Unchanged) | View |
| 2021-02-23 7:57 pm Sale | 13D | CELLULAR BIOMEDICINE GROUP, IN CBMG | NOVARTIS PHARMA AG | 0 0% | -1,458,257 (Position Closed) | View |
| 2021-02-16 4:10 pm Sale | 13G | BIOLINERX LTD SPONSORED ADR BLRX | NOVARTIS PHARMA AG | 4,999,995 1% | -5 (-0.00%) | View |
| 2021-02-12 4:24 pm Purchase | 13G | POSEIDA THERAPEUTICS INC PSTX | NOVARTIS PHARMA AG | 5,908,089 9.6% | 5,908,089 (New Position) | View |
| 2020-08-14 4:49 pm Purchase | 13D | GAMIDA CELL LTD GMDA | NOVARTIS PHARMA AG | 5,194,054 10.3% | 1,919 (+0.04%) | View |
| 2020-08-14 4:32 pm Unchanged | 13D | CELLULAR BIOMEDICINE GROUP, IN CBMG | NOVARTIS PHARMA AG | 1,458,257 7.5% | 0 (Unchanged) | View |